Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

Phase 0 Recruiting 30 enrolled Tongji Hospital Shenzhen Pregene Biopharma Co., Ltd. · collab

NaSequentialOpen-labelTreatment

Summary

A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.

Timeline

Start: 2024-07
Primary completion: 2027-07
Completion: 2028-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PRG-2311	Cell therapy	3.5e+07 cells	—
Subject	PRG-2311	Cell therapy	1e+08 cells	—
Subject	PRG-2311	Cell therapy	3e+08 cells	—

Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

Summary

Timeline

Drugs

Indications